Dive into an insightful analysis of the ADC commercial landscape in Asia. Curated by our expert Beacon Research Team, this report unveils invaluable competitive intelligence that will fuel your strategic decision-making.
What’s inside the report?
- Insights into the Asian ADC market over the past 10 years.
- Detailed company profiles of key players such as Lego Chem Biosciences and MediLink Therapeutics.
- The top 10 drug conjugate deals of 2023.
- An exploration of the prevalent drug targets shaping the landscape.
- An overview of deal types, highlighting the shift observed between 2022 and 2023.
- Insights into financing trends across various drug modalities.
To learn more about this report, or how Beacon ADC can enhance your data needs and provide fast insights, please book a research session below or contact us directly on beacon@hansonwade.com.
Speak with our team of experts
Our dedicated account and research teams are on hand to showcase how Beacon can help you find the answers to your ADC-related questions
About Beacon
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
